ReviewAnnals of diagnostic pathology2020
American Registry of Pathology Expert Opinions: The Spectrum of Lobular Carcinoma in Situ: Diagnostic Features and Clinical Implications.
Review in Annals of diagnostic pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 34 citations in OpenAlex.
- Clinical Outcomes of Lobular CarcinomaJournal of breast cancer · 2026Article
- Comprehensive characterization of invasive mammary carcinoma with lobular features: integrating morphology and E-cadherin immunohistochemistry patterns.Breast cancer (Tokyo, Japan) · 2025Article
- Immediate and delayed risk of breast cancer associated with classic lobular carcinoma in situ and its variants.Breast cancer research and treatment · 2024Article
- Does Non-Classic Lobular Carcinoma In Situ at the Lumpectomy Margin Increase Local Recurrence?Annals of surgical oncology · 2023Article
- Management of Lobular Neoplasia Diagnosed by Core Biopsy.The breast journal · 2023Observational
- Aquaporin-5 in breast cancer.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Review
- [Updated WHO classification of tumors of the breast].Der Pathologe · 2021Review
- Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- [Updated WHO classification of tumors of the breast: the most important changes].Der Pathologe · 2021Review
- Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.Breast cancer research : BCR · 2021Review
- Precision pathology as applied to breast core needle biopsy evaluation: implications for management.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
- Lobular carcinoma in situ: diagnostic criteria and molecular correlates.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
Abstract
This review reflects a collaboration between the American Registry of Pathology (the publisher of the Armed Forces Institute of Pathology Fascicles) and Annals of Diagnostic Pathology. It is part of a series of expert recommendations on topics encountered in daily practice. The authors, 4 pathologists with expertise in breast pathology and a breast surgeon with a clinical and research interest in lobular carcinoma in situ (LCIS), met by conference call in September 2019 to develop recommendations for evaluating and reporting LCIS. Herein, we summarize the diagnostic criteria of classic LCIS and LCIS subtypes according to the most recent WHO criteria, discuss how best to distinguish LCIS from ductal carcinoma in situ in problematic cases (including the uses and limitations of E-cadherin immunohistochemistry), and review outcome and management issues for patients with LCIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.